Skip to main content

Advertisement

SpringerLink
Log in

A prospective study of autoantibodies to Ezrin and pancreatic cancer risk

  • Brief report
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Purpose

No biomarker is available for pancreatic cancer early detection, but a small prospective European study involving 16 cases and 32 controls raised the possibility that anti-Ezrin autoantibodies may be associated with risk of pancreatic cancer. We aimed to validate this finding in a case–control study nested within a prospective study in the USA.

Methods

Levels of anti-Ezrin autoantibodies were examined using ELISA in pre-diagnostic plasma samples of 73 cases and 145 matched controls. Paired t test and paired signed rank tests were used to determine the difference between two groups, and conditional logistic regression was used to evaluate the association between anti-Ezrin autoantibody levels and risk of developing pancreatic cancer.

Results

No association was found between levels of anti-Ezrin plasma autoantibodies and subsequent risk of developing pancreatic cancer.

Conclusion

Anti-Ezrin autoantibodies did not appear to be useful as a plasma biomarker for early detection of pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics (2015). CA Cancer J Clin 65(1):5–29

    Article  PubMed  Google Scholar 

  2. Howlader N, Noone A, Krapcho M et al (2015) SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015

  3. Hunter KW (2004) Ezrin, a key component in tumor metastasis. Trends Mol Med 10(5):201–204

    Article  CAS  PubMed  Google Scholar 

  4. Meng Y, Lu Z, Yu S, Zhang Q, Ma Y, Chen J (2010) Ezrin promotes invasion and metastasis of pancreatic cancer cells. J Transl Med 8:61

    Article  PubMed  PubMed Central  Google Scholar 

  5. Capello M, Cappello P, Linty FC et al (2013) Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J Hematol Oncol 6:67

    Article  PubMed  PubMed Central  Google Scholar 

  6. Signorello LB, Hargreaves MK, Steinwandel MD et al (2005) Southern community cohort study: establishing a cohort to investigate health disparities. J Natl Med Assoc 97(7):972–979

    PubMed  PubMed Central  Google Scholar 

  7. Signorello LB, Hargreaves MK, Blot WJ (2010) The Southern Community Cohort Study: investigating health disparities. J Health Care Poor Underserved 21(1 Suppl):26–37

    Article  PubMed  PubMed Central  Google Scholar 

  8. Zaenker P, Ziman MR (2013) Serologic autoantibodies as diagnostic cancer biomarkers—a review. Cancer Epidemiol Biomark Prev 22(12):2161–2181

    Article  CAS  Google Scholar 

  9. Dumstrei K, Chen H, Brenner H (2016) A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection. Oncotarget 8(10):11151–11164

    Google Scholar 

  10. Clucas J, Valderrama F (2014) ERM proteins in cancer progression. J Cell Sci 127(Pt 2):267–275

    Article  CAS  PubMed  Google Scholar 

  11. Piao J, Liu S, Xu Y et al (2015) Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Exp Mol Pathol 98(1):1–6

    Article  CAS  PubMed  Google Scholar 

  12. Li J, Wei K, Yu H, Jin D, Wang G, Yu B (2015) Prognostic value of Ezrin in various cancers: a systematic review and updated meta-analysis. Sci Rep 5:17903

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors thank the study participants and research staff of the Southern Community Cohort Study for their contribution to this study. We thank Regina Courtney for laboratory assistance and Nancy Kennedy for assistance with editing and manuscript preparation. This study was funded by a training grant from the Fogarty International Center (D43 TW08313) and in part by the Shanghai Municipal Commission of Health and Family Planning (Grant Number: 20124370). The SCCS is funded by a grant from the National Cancer Institute (Grant Number: R01CA092447). Sample preparation and assays for anti-Ezrin autoantibodies were conducted at the Vanderbilt Survey and Biospecimen Shared Resource, which is supported in part by the Vanderbilt-Ingram Cancer Center (P30CA068485). Data on SCCS cancer cases used in this publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry, 4815W. Markham, Little Rock, AR 72205. The Arkansas Central Cancer Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry which participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi Cancer Registry.

Author information

Authors and Affiliations

  1. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN, 37232, USA

    Yaqiong Sun, Jie Wu, Hui Cai, Shuyang Wang, Qiaolan Liu, William J. Blot, Xiao Ou Shu & Qiuyin Cai

  2. Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China

    Yaqiong Sun

  3. West China School of Public Health, Sichuan University, Chengdu, Sichuan, China

    Qiaolan Liu

  4. International Epidemiology Institute, Rockville, MD, USA

    William J. Blot

Authors
  1. Yaqiong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jie Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuyang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qiaolan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William J. Blot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao Ou Shu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qiuyin Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiuyin Cai.

Ethics declarations

Conflicts of interest

No potential conflicts of interest were disclosed.

Additional information

Yaqiong Sun—In Memorium

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sun, Y., Wu, J., Cai, H. et al. A prospective study of autoantibodies to Ezrin and pancreatic cancer risk. Cancer Causes Control 27, 831–835 (2016). https://doi.org/10.1007/s10552-016-0757-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-016-0757-y

Keywords

Search

Navigation